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In large multicentre trials in diverse settings, there is uncertainty about the need to adjust 
for centre variation in design and analysis.  A key distinction is the difference between 
variation in outcome (independent of treatment) and variation in treatment effect.  Through 
re-analysis of the CRASH-2 trial (2010), this study clarifies when and how to use multi-level 
models for multicentre studies with binary outcomes.   
Methods: 
CRASH-2 randomised 20,127 trauma patients across 271 centres and 40 countries to either 
single-dose tranexamic acid or identical placebo, with all-cause death at 4 weeks the 
primary outcome.  The trial data had a hierarchical structure, with patients nested in 
hospitals which in turn are nested within countries. Reanalysis of CRASH-2 trial data 
assessed treatment effect and both patient and centre level baseline covariates as fixed 
effects in logistic regression models. Random effects were included to assess where there 
was variation between countries, and between centres within countries, both in underlying 
risk of death and in treatment effect.   
Results: 
In CRASH-2 there was significant variation between countries and between centres in death 
at 4 weeks, but absolutely no differences between countries or centres in the effect of 
treatment. Average treatment effect was not altered after accounting for centre and 
country variation in this study.  
Conclusions 
 It is important to distinguish between underlying variation in outcomes and variation in 
treatment effects, the former is common but the latter is not. Stratifying randomisation by 
centre overcomes many statistical problems and including random intercepts in analysis 
may increase power and decrease bias in mean and standard error estimates. 
Trial registration: Current Controlled Trials ISRCTN86750102, 




Multi-centre trials, random effects, heterogeneity
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Background 
Large phase III randomised controlled trials (RCTs) often involve many centres, sometimes in 
several countries. Outcomes may vary, either due to centre differences, for example in 
infrastructure and concomitant treatment protocols, or due to environmental or nutritional 
variation in patient populations. For example, Papachristophi et al showed that UK cardiac 
surgery outcomes vary substantially due to patient characteristics, operating surgeon and 
centre1. When analysing RCTs carried out in diverse settings, it is important to consider 
these sources of variation in outcome in order that the effect of the treatment of interest is 
estimated both accurately and precisely.  
In primary trial analysis, important patient characteristics measured at baseline, especially 
those used to stratify randomisation, may be adjusted for in trial analysis and this has been 
shown to increase precision of the estimate for a Normally distributed effect2. This has also 
been shown for survival data15.  For moderately sized RCTs and where centre is not included 
in the randomisation process, failure to adjust for centre can cause biased standard errors 
of the estimated treatment effect, leading to incorrect type 1 error and a reduction in 
power3. For very large, stratified (by centre) trials, omitting centre from the primary analysis 
may be justified, since stratified randomisation will guard against bias in treatment effect 
estimates and the size of the trial will ensure adequate power. This was the case for the 
CRASH-2 placebo-controlled RCT of tranexamic acid in trauma patients, the main example in 
this study4. However, in discussing CRASH-2, Gruen et al raised concerns about the efficacy 
of tranexamic acid for patients treated to modern trauma care standards, as CRASH-2 was 
carried out in mostly low to middle income countries and outcomes varied substantially.5  It 
is not clear whether this concern surrounded variation in treatment effect or in the 
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underlying centre-specific outcomes and the difference between these two is often 
conflated.  
Although randomisation in multicentre trials is often stratified by centre, including many 
centres as factors in the analysis can cause computational problems and make trial results 
difficult to interpret. One option is to include centres as random effects, whereby their 
results are viewed as a sample of centre outcomes and overall results pertain to the 
average6. A random effects model effectively reduces the number of parameters to be 
estimated and allows exploration of covariates acting at the country and centre levels, 
rather than the individual level. One study that used random effects models in this context 
(Lingsma et al, 2011) found that large between-centre differences in outcomes did not 
affect the estimate or statistical significance of the overall treatment effect in a traumatic 
brain injury trial8.  We aim to replicate this study using a larger trial, and extend the 
methods in order to (i) demonstrate use and presentation of random effects for multicentre 
RCTs through reanalysis of the CRASH-2 RCT and (ii) clarify the implication for different RCT 
design options when the primary outcome is binary.  
Specifically, we aim to:  
• Assess variance in outcome, and treatment effect, between countries and between 
centres within countries, in the CRASH-2 trial;  
• Clarify the interpretation of different sources of variation between centres and 
investigate centre-level covariates;  
• Compare the treatment effect from an unadjusted analysis with that from analysis 




The CRASH-2 trial, published in 2010 was a large, multicentre RCT comparing tranexamic 
acid with placebo in adult trauma patients at risk of significant bleeding4. The trial included 
20,211 patients recruited from 274 hospitals in 40 countries, between May 2005 and 
January 2010. We focus on the primary outcome of death in hospital within 4 weeks of 
injury. In the trial tranexamic acid significantly reduced all-cause mortality risk (relative risk 
0.91, 95% CI 0.85 to 0.97; p=0.0035).  Patients were allocated to trial arm using a 
minimisation algorithm which ensured balance between the groups in age, sex, time since 
injury, type of injury (blunt or penetrating), Glasgow Coma Score, systolic blood pressure, 
respiratory rate, central capillary refill time and country. Although these factors were 
considered important predictors of outcome, the primary analysis was unadjusted and did 
not allow for differences in outcome or treatment effect between centres or between 
countries.  Given the process of achieving balance across major predictive factors and the 
very large size of the trial, unadjusted analysis is justified. However, given the concerns of 
some investigators5, a secondary analysis exploring centre and country differences is of 
interest. 
Analysis methods 
(See Appendix A for details of statistical models). In contrast to the original analysis of 
CRASH-2, we used a Binary logistic regression model, since this is common for trial analysis 
and more suitable for small trials or uncommon outcomes. Ignoring centre and country 
effects, the log(odds) of death for a patient takes the form, 
𝛽0  +  𝛽1 𝑇 +  𝜷𝟐
𝑻𝑿 
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where the intercept 𝛽0 is the log(odds) of death in the control (placebo) group with all 
covariates equal to zero, treatment coefficient 𝛽1 is the log(odds ratio) for the treatment 
group relative to control (all other factors being equal), 𝑇 = 1 if treated and 𝑇 = 0 if 
control, and 𝜷𝟐
𝑻𝑿 represents coefficients and values for all other variables in the analysis. In 
RCTs 𝑿 usually includes variables used in the assignment of patients to treatment groups.  
These baseline characteristics are included to remove systematic variation due to patient 
factors and to improve precision of the treatment effect.   
Random effects models 
In the simple model above, the underlying probability of death and the effect of treatment 
may depend on patient characteristics but are otherwise constant across centres and 
countries. Equivalence of outcomes across centres may be unlikely when trials are 
conducted in diverse settings. One option is to allow for variation between centres using 
random effects.  If variation in outcome is expected a centre specific term is added to the 
regression: 
𝛽0 + 𝑢0𝑖  +  𝛽1 𝑇 +  𝜷𝟐
𝑻𝑿 
where 𝑢0𝑖  denotes a random effect for centre 𝑖, which represents the difference in 
outcomes between each centre and the average outcome. The 𝑢0𝑖  are usually assumed to 
vary according to a Normal distribution with mean zero. Allowing this kind of variation for 
the intercept (𝛽0) illustrated by 𝑢0𝑖  above, represents the case where the underlying 
outcomes vary but the treatment effect is constant. We note that both trial arms are subject 
to this type of variation. 
If variation in both outcome and treatment effect is expected, this adds another centre 
specific term to the regression: 
𝛽0 + 𝑢0𝑖  + (𝛽1 + 𝑢1𝑖)𝑇 +  𝜷𝟐
𝑻𝑿 
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where 𝑢1𝑖  denotes a random effect on the treatment coefficient for centre 𝑖, which again is 
assumed to be from a population of treatment effects, usually assumed to be Normally 
distributed. Allowing centre variation in the treatment coefficient represents the case 
where the treatment affects patients differently in different centres. Although the 
intervention is only applied in one trial arm, it is the difference in outcomes between 
treated and controls that provides the data from which random treatment effects are 
calculated. In the above, two levels are assumed for the data, centres and patients within 
centres, but in practice the data structure may be more complex. In CRASH-2 the data have 
a three-level hierarchical structure, countries, centres within countries and patients within 
centres. In this case we include additional random effects representing country variation. 
Intra-class correlation coefficient (ICC) 
The total variation in outcomes between patients, after adjusting for differences between 
patients, includes variation due to unexplained centre differences. Any bias and loss of 
power due to not accounting for between-centre variance depends on how correlated 
patients in the same centre are compared with patients from different centres.   This is 
quantified by the intra-class correlation coefficient (ICC), which measures how much of the 
total variability is explained by the between-centre variance.  If the ICC is one, outcomes for 
participants in the same centre are perfectly correlated and if ICC is zero, outcomes for 
participants in the same centre have zero correlation.  For three level hierarchies, both 
country and centre variation contributes to the total variation, so that both have an ICC.  
Statistical Software 





Individual patient data from CRASH-2 were used4 (summary statistics in Table 1). Four of 
20,211 randomised patients withdrew their consent. Eighty patients with no outcome 
recorded and forty-two patients with one or more missing covariate (age, time from injury, 
Glasgow Coma Score (GCS) and systolic blood pressure (SBP)) were excluded.  The 
remaining 20,085 patients were included in the all-cause mortality analysis. Because of the 
small number of exclusions, no additional analysis of missing data were undertaken. The 
number of patients entered into the trial by individual centres ranged from 1 to 1330, 
median 22.5 and interquartile range 64.  The number of trial centres in each country ranged 
from 1 (13 countries) to 84, median 3 and interquartile range 5.25. 
Overall, 3076 patients died within 4 weeks, 1463 (14.5%) in the tranexamic acid group and 
1613 (16.0%) in the control group. The crude death rate varied substantially across 
countries; for example 23.7% (484/2040) patients died within 4 weeks in Nigerian trial 
centres, whilst centres contributing small number of patients, such as Serbia & Montenegro 
(n=1), Singapore (n=2) and Czech Republic (n=17) had no deaths during the trial (Figure 1). 
 
Figure 1. Percentage of patients in CRASH-2 countries that died within 4 weeks of randomisation; 
the number of patients randomised in each country is provided. 
 
Random effects structure 
Adjusting for baseline patient characteristics, there was significant variation in underlying 
outcome between countries and between centres within countries (Table 2). The ICC 
suggested that centres accounted for 16.4% of the total variation in death rates; 95% 
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intervals in centre-specific odds ratio, relative to the average in the same country ranged 
from 0.29 to 3.50. That is, the range is from approximately a third to three times the 
average odds of death in the same country. The corresponding ICC for countries, adjusted 
for patient characteristics and centre variance, suggested that country differences 
accounted for 6.0% of the variation in death rates; 95% intervals for the odds ratios ranged 
from 0.39 to 2.59 relative to the country average.  
In contrast, there was no variation between centres or between countries in treatment 
effect estimates, with the variance between country random effects converging to zero.  
Figure 2 shows approximate odds ratios of death (relative to the average) for each centre in 
the top panel and the corresponding estimates for the odds ratios for treatment effect in 
the lower panel. In order to explore concerns about geographical variation in outcomes, in 
Figure 3 participating countries are shaded according to their log(odds ratio) for death, 
relative to the average (top panel) and according to the log(odds ratio) for treatment effect 
(lower panel). This illustrates that countries with high and low odds of death appear to be 
distributed randomly across the world and that there is no variation in the effectiveness of 
tranexamic acid.   
 
Figure 2. CRASH-2 centre-specific odds ratios (95% confidence intervals) for death in 4 weeks, relative to 
the average (top panel) and centre-specific treatment effects (95% confidence intervals), relative to the 
average (lower panel) 
 
Figure 3. CRASH-2 country-specific odds ratios for death in 4 weeks, relative to the average (top panel) 
and country-specific treatment effects (95% confidence intervals), relative to the average (lower panel) 
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 Treatment and other fixed effects  
The final model for all-cause mortality is given in the appendix, and included SBP, SBP-
squared, age, age-squared, GCS, time to treatment categories and injury type. Despite 
adjustment for these patient characteristics and for centre/country variation in outcomes, 
the point estimate of the treatment effect increases only slightly after adjustment for 
patient characteristics (Appendix B, Table 1) and returns to the original estimate after 
further adjustment for between-country and centre variance.  The statistical significance of 
the treatment effect decreases somewhat after adjusting for patient characteristics 
(p=0.018), but increases after accounting for between centre and country variance.   
Table 2. Full results from final model 
Covariate Point estimate Standard error 95% CI P-value 
Treatment (active) 0.89 0.042 0.81 to 0.98 0.014 
Time from injury (>1-3 hours) 0.86 0.054 0.76 to 0.97 0.015 
Time from injury (>3 hours) 0.75 0.051 0.66 to 0.86 <0.0001 
Age (years) 0.99 0.007 0.98 to 1.01 0.332 
Age2 1.00 0.00008 1.00 to 1.00 <0.0001 
SBP (mmHg) 0.93 0.004 0.93 to 0.94 <0.0001 
SBP2 1.00 0.00002 1.00 to 1.00 <0.0001 
GCS (Moderate) 0.21 0.015 0.18 to 0.24 <0.0001 
GCS (Mild) 0.07 0.004 0.06 to 0.08 <0.0001 
Injury type (penetrating) 0.81 0.054 0.71 to 0.93 0.002 
 
Variance of country intercept: 0.236 




Explaining between-centre/country variance with centre/country level variables 
One benefit of random effects models is the opportunity to assess centre/country-level 
variables associated with better and worse outcomes. In CRASH-2 mean age, proportion of 
cases with severe GCS, proportion with penetrating injuries and average time to treatment 
for each centre, as well as income level category for each country could be assessed 
(summary statistics in Table 3). The proportion of patients with severe GCS in a centre was 
associated with increased death rates. For every 10% increase in percentage of cases with 
severe GCS, the odds ratio was 11.5 (95% CI 6.37, 20.7) (Appendix B, Table 2). Death rates 
were also higher in low and middle income countries relative to high income countries (odds 
ratio 1.25 (1.13, 1.37)). 













Centre level characteristics Mean (range) 
Centre mean age (years) 36.3 (16.0-79.0) 
GCS Severe average centre proportion 0.23 (0-1) 
GCS Moderate average centre proportion 0.12 (0-1) 
GCS Mild average centre proportion 0.65 (0-1) 
Time to treatment ≤1 hour average centre proportion 0.06 (0-1) 
Time to treatment 1-3 hours average centre proportion 0.40 (0-1) 
Time to treatment >3 hours average centre proportion 0.53 (0-1) 
Penetrating injuries average centre proportion 0.25 (0-1) 
Blunt* injuries average centre proportion 0.75 (0-1) 
Country level characteristics  
Proportion in low/lower middle income countries  0.51 
Proportion in upper middle/high income countries 0.49 
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Investigating period effects 
In order to assess whether patients recruited closer in time had more similar results, an 
exchangeable, four-level hierarchical model was fitted (patient within 6-month time period 
within centre within country).  There was significant evidence that results varied by time 
period (p=0.0002 for likelihood ratio test comparison with three-level model), although the 
variation in outcomes due to time period was only 2% of the total variation. Fitting time 
period as a fixed effect suggested that patients recruited later had lower odds of death.  
However, treatment effect was not related to period of recruitment in either model. (See 
Appendix B for results). 
Discussion 
Summary of results 
In our reanalysis of CRASH-2, accounting for the large between-centre and between-country 
variation did not change the estimated treatment effect for all-cause death within 4 weeks, 
although the statistical significance was slightly increased (p=0.018 to p=0.014). The reason 
for this is that the estimated variation in the effect of tranexamic acid between countries 
(Figure 3), and between centres within countries (figure 2), is essentially zero. This is 
consistent with secondary analysis of the MRC CRASH trial7 (2005), which investigated the 
effect of corticosteroids on death in 10,008 patients with head injuries. Lingsma et al (2011) 
found that large between-centre differences in outcomes did not affect the estimate or 
statistical significance of the overall treatment effect in this trial9.   
Conversely, the forest plots (Figure 2) and maps (Figure 3) clearly illustrated variation in 
outcome without treatment by centre and by country respectively, after adjusting for 
patient baseline characteristics.   
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Discussion and interpretation of our results 
It’s important to note that marginal models (Generalised Estimating Equations) could have 
been used if the aim was only to adjust for clustering.  However, random effects models 
were chosen as they allowed us to estimate contributions of variance from 
countries/centres and investigate influence of available covariates at centre and country 
level. 
The reasons for variation in outcomes were not clear. At centre level, some variance in 
outcomes could be explained by the higher number of severe GCS cases in some centres, 
but the trial dataset did not include many centre-level covariates to allow detailed 
exploration. At the country level, outcomes were generally worse in low and middle income 
countries, but there was no clear geographical pattern, with lower than average odds of 
death evident in countries as diverse as China, Kenya and Canada.  Moreover, CRASH-2 did 
not contain detailed information on country-specific health service provision and 
infrastructure.  We note that countries (or centres) with a small number of patients in the 
trial tended to have extreme results (very high or low death rates). However, small centres 
may suffer from small sample bias (tendency to have extreme outcomes by chance), so that 
care has to be taken when interpreting these figures. 
In CRASH-2 the effect of tranexamic acid did not vary across centres.  Gruen et al raised 
concerns about generalisability of CRASH-2 trial results applied to high income settings, 
since most trial participants were treated in low and middle income countries5.  This seems 
to conflate variation in outcomes (independent of treatment) and variation in treatment 
effects. In a response, Roberts and Prieto-Marino illustrated how two centres could have 
very different risks of death in the control group, but the relative risks comparing the 
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treatment group and control group within the centres can still be the same9.  The biological 
mechanism by which tranexamic acid works (stopping clot breakdown and reducing heavy 
bleeding) is not expected to vary between patients (and therefore centres), so that results 
due to bleeding-related deaths are generalizable, although deaths from other causes may 
differ.  The trial treatment was a single dose of tranexamic acid or matched placebo, so that 
there was little variation in delivery of treatment and selection bias was avoided. Our 
reanalysis of CRASH-2 supported the homogeneity of treatment effect on death at 4 weeks 
across countries and centres, including high income countries.   
Variation in the outcome or treatment effect can depend on the choice of statistical 
model10. However, our results were almost identical whether our analysis used odds ratios 
(from logistic regression) or risk ratios (from Poison regression) to describe treatment 
effects.  We note that this result may not generalisable to (open label) trials of more 
complex interventions, such as surgery or mental health interventions, where the treatment 
delivery may depend on the health provider11.  
Studies of complex surgical interventions have reported changes in outcomes as a trial 
progresses16. Hence, studies may warrant investigation of a ‘period effect’, where patients 
recruited closer in time have more similar results due to protocol changes, learning effects 
or trial experience.  In the CRASH-2 trial, time period explained 2% of the total variation in 
outcome, but it was statistically significant at traditional levels, with later patients having 
lower odds of death.  This was unexpected in this double-blind trial of a single episode 
treatment and may result from a general shift towards recruiting slightly lower-risk patients 
over time, as experience in the trial increases. The treatment effect was not related to 
period of recruitment. 
How it fits with literature/guidelines 
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Currently, there is no consensus on when and how centre variance should be adjusted for in 
multicentre trials.  The ICH-E9 guideline on multicentre trials focuses on possible 
heterogeneity of treatment effect and on avoiding having few subjects in some centres12.  
For trials with positive treatment effects and appreciable numbers of patients per centre, it 
recommends an exploratory analysis to identify any heterogeneity of treatment effects 
across centres and to assess its impact on generalisability of results. It does not strongly 
suggest that centre differences in outcomes must be accounted for in primary trial analysis. 
ICH-E9 guidelines12 also discuss the use of random effects models for exploring 
heterogeneity of the treatment effects, suggesting that centre effects on outcome and 
treatment effects are especially relevant when the number of sites is large.  Including 
centres as fixed effects is appropriate if the number of centres in the trial is small or if 
interest surrounds estimation of centre effects themselves (see for example, Rabe-Hesketh 
and Skrondal13).  However, if the number of centres is large, with some recruiting only a few 
patients, or if centres are viewed as a sample of the wider population of centres that might 
benefit from treatment, but are not of interest themselves, a random effects model is more 
appropriate.   
Simulation studies have been carried out to look at any change in power when accounting 
for between-centre variation.  Kahan and Morris found that Type 1 error rates became large 
when between centre variation or clustering was ignored for both continuous and binary 
outcomes3 14.  Our own simulation studies based on data with the same structure as CRASH-
2 also found that, for binary outcomes, Type 1 error rates were substantially inflated when 
between-centre variance was ignored in the analysis, particularly if centres had unequally 
sized treatment allocation.    
Strengths and weaknesses 
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The large sample size in the CRASH-2 trial, and the small amount of missing data meant that 
there was high power and small chance of bias in estimation of the overall treatment effect.  
The large number of centres and countries also allows reliable estimation of the distribution 
of outcomes and treatment effects. Thus, we can be confident in conclusions around centre 
variation and (lack of) treatment effect heterogeneity by country. A limitation was the lack 
of centre and country level variables in the CRASH-2 dataset, which could have helped 
explain geographical and health service factors that contribute to different outcomes. 
Conclusions 
In conclusion, in multicentre studies with binary outcome, clustering should be accounted 
for to maximize power and reduce bias in treatment effect estimates and standard errors. 
Randomisation should be stratified by centre where possible; if not possible, analysis should 
adjust for clustering by centre. Random effects models are an efficient way to do this when 
the number of centres is large (>=20), treatment assignments are unequal within centres 
and where there are few patients per centre.  We recommend that care should be taken 
when interpreting between-centre variation, in particular recognising that the treatment 
effect is not likely to vary by country or income setting if there is an established biological 
mechanism. However, the underlying risk of death is likely to vary across different settings. 
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Table 1. Summary statistics for patient characteristics in the CRASH-2 trial 











34.6    (14.14) 
2,777  (27.6%) 
3,006  (29.9%) 
1,966  (19.5%) 
2,311  (23.0%) 
 
34.5    (14.39) 
2,838  (28.2%) 
3,070  (30.5%) 
1,832  (18.2%) 






8,413  (83.6%) 
1,647  (16.4%) 
0 
 
8,456  (84.0%) 
1,610  (15.99%) 
1 (0.01%) 






1,789  (17.8%) 
1,349  (13.4%) 
6,915  (68.7%) 
7  (<1%) 
 
1,830  (18.2%) 
1,344  (13.4%) 
6,877  (68.3%) 
16  (<1%) 







3.22    (19.99) 
3,747  (37.3%) 
3,037  (30.2%) 
3,272  (32.5%) 
4  (0.04%) 
 
3.26    (20.03) 
3,705  (36.8%) 
2,996  (29.8%) 
3,362  (33.4%) 
4  (0.04%) 




6,788  (67.5%) 
3,272  (32.5%) 
6,817  (67.7%) 
3,250  (32.3%) 






1,562  (15.5%) 
1,609  (16.0%) 
6,878  (68.4%) 
11  (<1%) 
 
1,599  (15.9%) 
1,689  (16.8%) 
6,761  (67.2%) 
18  (<1%) 
28-day mortality 
Dead (all-cause) 
Dead due to bleeding 
 
1,463  (14.5%) 
489  (4.9%) 
 
1,613  (16.0%) 
575  (5.7%) 
*Includes patients with both blunt and penetrating and those with only blunt injuries 
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Figure 1. Percentage of patients in CRASH-2 countries that died within 4 weeks of 






Figure 2. CRASH-2 centre-specific odds ratios (95% confidence intervals) for death in 4 
weeks, relative to the average (top panel) and centre-specific treatment effects (95% 






























Figure 3. CRASH-2 country-specific odds ratios for death in 4 weeks, relative to the average 
(top panel) and country-specific treatment effects (95% confidence intervals), relative to the 
average (lower panel) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
